201 related articles for article (PubMed ID: 23497646)
1. gSG6-P1 salivary biomarker discriminates micro-geographical heterogeneity of human exposure to Anopheles bites in low and seasonal malaria areas.
Sagna AB; Sarr JB; Gaayeb L; Drame PM; Ndiath MO; Senghor S; Sow CS; Poinsignon A; Seck M; Hermann E; Schacht AM; Faye N; Sokhna C; Remoue F; Riveau G
Parasit Vectors; 2013 Mar; 6():68. PubMed ID: 23497646
[TBL] [Abstract][Full Text] [Related]
2. Human IgG response to a salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level exposure to Anopheles bites.
Poinsignon A; Cornelie S; Ba F; Boulanger D; Sow C; Rossignol M; Sokhna C; Cisse B; Simondon F; Remoue F
Malar J; 2009 Aug; 8():198. PubMed ID: 19674487
[TBL] [Abstract][Full Text] [Related]
3. Utility of plasma anti-gSG6-P1 IgG levels in determining changes in Anopheles gambiae bite rates in a rural area of Cameroon.
Nguetsa GC; Elanga-Ndille E; Essangui Same EG; Nganso Keptchouang T; Mandeng SE; Ekoko Eyisap W; Binyang JA; Fogang B; Nouage L; Piameu M; Ayong L; Etang J; Wanji S; Eboumbou Moukoko CE
Sci Rep; 2024 Jun; 14(1):14294. PubMed ID: 38906949
[TBL] [Abstract][Full Text] [Related]
4. IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to Anopheles bites in urban areas of Dakar region, Sénégal.
Drame PM; Machault V; Diallo A; Cornélie S; Poinsignon A; Lalou R; Sembène M; Dos Santos S; Rogier C; Pagès F; Le Hesran JY; Remoué F
Malar J; 2012 Mar; 11():72. PubMed ID: 22424570
[TBL] [Abstract][Full Text] [Related]
5. Plasmodium falciparum infection during dry season: IgG responses to Anopheles gambiae salivary gSG6-P1 peptide as sensitive biomarker for malaria risk in Northern Senegal.
Sagna AB; Gaayeb L; Sarr JB; Senghor S; Poinsignon A; Boutouaba-Combe S; Schacht AM; Hermann E; Faye N; Remoue F; Riveau G
Malar J; 2013 Aug; 12():301. PubMed ID: 23988032
[TBL] [Abstract][Full Text] [Related]
6. Use of anti-gSG6-P1 IgG as a serological biomarker to assess temporal exposure to Anopheles' mosquito bites in Lower Moshi.
Kassam NA; Kulaya N; Kaaya RD; Schmiegelow C; Wang CW; Kavishe RA; Alifrangis M
PLoS One; 2021; 16(10):e0259131. PubMed ID: 34705869
[TBL] [Abstract][Full Text] [Related]
7. Preliminary validation of the use of IgG antibody response to Anopheles gSG6-p1 salivary peptide to assess human exposure to malaria vector bites in two endemic areas of Cameroon in Central Africa.
Cheteug G; Elanga-Ndille E; Donkeu C; Ekoko W; Oloume M; Essangui E; Nwane P; NSango SE; Etang J; Wanji S; Ayong L; Eboumbou Moukoko CE
PLoS One; 2020; 15(12):e0242510. PubMed ID: 33382730
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Malaria Urban Risk Using an Immuno-Epidemiological Biomarker of Human Exposure to
Traoré DF; Sagna AB; Adja AM; Zoh DD; Lingué KN; Coulibaly I; N'Cho Tchiekoi B; Assi SB; Poinsignon A; Dagnogo M; Remoue F
Am J Trop Med Hyg; 2018 May; 98(5):1353-1359. PubMed ID: 29512479
[TBL] [Abstract][Full Text] [Related]
9. Spatial Assessment of Contact Between Humans and Anopheles and Aedes Mosquitoes in a Medium-Sized African Urban Setting, Using Salivary Antibody-Based Biomarkers.
Sagna AB; Kassié D; Couvray A; Adja AM; Hermann E; Riveau G; Salem G; Fournet F; Remoue F
J Infect Dis; 2019 Aug; 220(7):1199-1208. PubMed ID: 31152664
[TBL] [Abstract][Full Text] [Related]
10. First attempt to validate the gSG6-P1 salivary peptide as an immuno-epidemiological tool for evaluating human exposure to Anopheles funestus bites.
Poinsignon A; Samb B; Doucoure S; Drame PM; Sarr JB; Sow C; Cornelie S; Maiga S; Thiam C; Rogerie F; Guindo S; Hermann E; Simondon F; Dia I; Riveau G; Konate L; Remoue F
Trop Med Int Health; 2010 Oct; 15(10):1198-203. PubMed ID: 20723184
[TBL] [Abstract][Full Text] [Related]
11. Human exposure to Anopheles farauti bites in the Solomon Islands is not associated with IgG antibody response to the gSG6 salivary protein of Anopheles gambiae.
Pollard EJM; Patterson C; Russell TL; Apairamo A; Oscar J; Arcà B; Drakeley C; Burkot TR
Malar J; 2019 Oct; 18(1):334. PubMed ID: 31570113
[TBL] [Abstract][Full Text] [Related]
12. Variation in exposure to Anopheles gambiae salivary gland peptide (gSG6-P1) across different malaria transmission settings in the western Kenya highlands.
Badu K; Siangla J; Larbi J; Lawson BW; Afrane Y; Ong'echa J; Remoue F; Zhou G; Githeko AK; Yan G
Malar J; 2012 Sep; 11():318. PubMed ID: 22963464
[TBL] [Abstract][Full Text] [Related]
13. Human IgG responses to Aedes mosquito salivary peptide Nterm-34kDa and its comparison to Anopheles salivary antigen (gSG6-P1) IgG responses measured among individuals living in Lower Moshi, Tanzania.
Kassam NA; Laswai D; Kulaya N; Kaaya RD; Kajeguka DC; Schmiegelow C; Wang CW; Alifrangis M; Kavishe RA
PLoS One; 2022; 17(10):e0276437. PubMed ID: 36301860
[TBL] [Abstract][Full Text] [Related]
14. An. gambiae gSG6-P1 evaluation as a proxy for human-vector contact in the Americas: a pilot study.
Londono-Renteria B; Drame PM; Weitzel T; Rosas R; Gripping C; Cardenas JC; Alvares M; Wesson DM; Poinsignon A; Remoue F; Colpitts TM
Parasit Vectors; 2015 Oct; 8():533. PubMed ID: 26464073
[TBL] [Abstract][Full Text] [Related]
15. IgG antibody responses to Anopheles gambiae gSG6-P1 salivary peptide are induced in human populations exposed to secondary malaria vectors in forest areas in Cameroon.
Ndo C; Elanga-Ndille E; Cheteug G; Metitsi RD; Wanji S; Moukoko CEE
PLoS One; 2022; 17(11):e0276991. PubMed ID: 36355922
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effectiveness of malaria vector control measures in urban settings of Dakar by a specific anopheles salivary biomarker.
Drame PM; Diallo A; Poinsignon A; Boussari O; Dos Santos S; Machault V; Lalou R; Cornelie S; LeHesran JY; Remoue F
PLoS One; 2013; 8(6):e66354. PubMed ID: 23840448
[TBL] [Abstract][Full Text] [Related]
17. Use of an Anopheles Salivary Biomarker to Assess Malaria Transmission Risk Along the Thailand-Myanmar Border.
Ya-Umphan P; Cerqueira D; Parker DM; Cottrell G; Poinsignon A; Remoue F; Brengues C; Chareonviriyaphap T; Nosten F; Corbel V
J Infect Dis; 2017 Feb; 215(3):396-404. PubMed ID: 27932615
[TBL] [Abstract][Full Text] [Related]
18. Wide cross-reactivity between Anopheles gambiae and Anopheles funestus SG6 salivary proteins supports exploitation of gSG6 as a marker of human exposure to major malaria vectors in tropical Africa.
Rizzo C; Ronca R; Fiorentino G; Mangano VD; Sirima SB; Nèbiè I; Petrarca V; Modiano D; Arcà B
Malar J; 2011 Jul; 10():206. PubMed ID: 21794142
[TBL] [Abstract][Full Text] [Related]
19. Exploring the heterogeneity of human exposure to malaria vectors in an urban setting, Bouaké, Côte d'Ivoire, using an immuno-epidemiological biomarker.
Traoré DF; Sagna AB; Adja AM; Zoh DD; Adou KA; Lingué KN; Coulibaly I; Tchiekoi NB; Assi SB; Poinsignon A; Dagnogo M; Remoue F
Malar J; 2019 Mar; 18(1):68. PubMed ID: 30857543
[TBL] [Abstract][Full Text] [Related]
20. Humoral response to the Anopheles gambiae salivary protein gSG6: a serological indicator of exposure to Afrotropical malaria vectors.
Rizzo C; Ronca R; Fiorentino G; Verra F; Mangano V; Poinsignon A; Sirima SB; Nèbiè I; Lombardo F; Remoue F; Coluzzi M; Petrarca V; Modiano D; Arcà B
PLoS One; 2011 Mar; 6(3):e17980. PubMed ID: 21437289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
